Summary
The response to hepatitis B (HBV) vaccination was studied in 32 breast cancer patients who were HBV antigen- and antibody-negative at the time of diagnosis. Ten of the patients included into the study received radical mastectomy without adjuvant therapy, 15 patients underwent breast-conserving surgery with subsequent irradiation with or without tamoxifen treatment, and 7 patients were treated by modified radical mastectomy plus adjuvant chemotherapy. Eight patients received the first dose of vaccine 3 months after irradiation therapy. Seven patients were first vaccinated 6 months following irradiation therapy. Seven healthy age-matched persons were vaccinated as controls. Antibody response in the patients was significantly delayed. Four weeks after the second vaccination 6 out of 7 controls showed a significant (>10IU/ml) HBs antibody titer, while only 6 out of 32 patients responded. In addition, HBs antibody titers were also significantly lower after the second vaccination even in those patients treated with surgery alone, although they were first vaccinated 3 months after surgery and had no residual tumors. This difference disappeared after the second booster immunization, at which time the frequency of significant antibody titers and the levels of HBs antibody titers were comparable between patients and controls. As the population of patients undergoing treatment for breast cancer is increasing, additional studies are needed to determine optimal immunization regimens in this group of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A: Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303: 803–841, 1980
Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, Sadovsky R, Kellner A: Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and subtype cross-protection. N Engl J Med 307: 1481–1486, 1982
Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93: 579–582, 1980
Regenstein FG, Perillo RP, Bodicky C, Stern K, Zelman S: Clinical and immunologic features of chronic dialysis patients who fail to respond to hepatitis B vaccine. Vaccine 3: 27–30, 1985
Grob PJ, Binswanger U, Zaruba K: Immunogenicity of a hepatitis subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 3: 43–52, 1983
Galbraith RM, Eddleston ALWF, Williams R, Zuckerman AJ, Bagshawe KD: Fulminant hepatic failure in leukemia and chorioncarcinoma related to withdrawal of cytotoxic drug therapy. Lancet ii: 528–530, 1975
Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449, 1982
Weitberg AB, Weitzmann SA, Watkins E, Hinkle C, O'Rourke S, Dienstag JL: Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 3: 718–722, 1985
Bonadonna G, Valagussa P,et al. CMF adjuvant chemotherapy in operable breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant Therapy of Cancer. Grune and Stratton, New York, 1979, pp 227–237
Bast RC: Effects of cancers and their treatment on host immunity. In: Holland JF, Frey E III (eds) Cancer Medicine. Lea and Febiger, Philadelphia, 1982, pp 1134–1140
Cook JM, Gualde N, Hessel L, Mounier M, Michel JP, Denis F, Ratinauds MH: Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol 109: 89–96, 1987
Zielinski CC, Stuller I, Dorner F, Pötzi P, Müller Ch, Eibl MM: Impaired primary, but not secondary, immune response in breast cancer patients under adjuvant chemotherapy. Cancer 58: 1648–1652, 1986
Moroz C, Giler S, Kupfer B, Urca I: T-lymphocytes and ferritin bearing lymphocytes in breast cancer. Cancer Immunol Immunother 3: 101–105, 1977
Moroz C, Bessler H: Ferritin as a marker in malignancy. In: De Sousa M, Brock J (eds) Ferritin in Immunity. Cancer and Inflammation. John Wiley and Sons, New York, Philadelphia, 1989, pp 283–301.
Rosen HR, Stierer M, Göttlicher J,et al. Determination of placental ferritin positive (PLF+)-T-lymphocytes is an effective marker of early stages of breast cancer [Abs 996]. Proc Am Assoc Cancer Res 32: 167, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosen, H.R., Stierer, M., Wolf, H.M. et al. Impaired primary antibody responses after vaccination against hepatitis B in patients with breast cancer. Breast Cancer Res Tr 23, 233–240 (1992). https://doi.org/10.1007/BF01833520
Issue Date:
DOI: https://doi.org/10.1007/BF01833520